Elevated plasma levels of Krebs von den Lungen-6 and geographic appearance on high-resolution computed tomography are associated with diffuse alveolar damage in autopsy cases of acute respiratory distress syndrome: a retrospective study

Ryosuke Imai1*, Daisuke Yamada2, Yutaka Tomishima1, Tomoaki Nakamura1, Clara So1, Shosei Ro1, Kohei Okafuji1, Atsushi Kitamura1, Torahiko Jinta1 and Naoki Nishimura1

Abstract

Background: Although diffuse alveolar damage (DAD) is a histopathological hallmark of acute respiratory distress syndrome (ARDS), its detection without lung biopsy is challenging. In patients with ARDS, the specificity of the Berlin definition to diagnose DAD as a reference standard is not adequately high, making it difficult to adequately diagnose DAD. The purpose of this study was to investigate the relationship between DAD and clinical findings, including KL-6 and geographic appearance, in ARDS patients and to identify more specific diagnostic criteria for DAD.

Methods: Among all adult autopsy cases at a tertiary hospital in Japan between January 2006 and March 2021, patients with ARDS who met the Berlin definition criteria were included. The patients’ conditions were classified according to histopathological patterns as DAD or non-DAD, and clinical characteristics, laboratory data, and high-resolution computed tomography (HRCT) findings were compared between the two groups.

Results: During the study period, 27 met the Berlin definition (median age: 79 years, 19 men), of whom 18 (67%) had DAD and 9 (33%) did not. In the non-DAD group, histopathologic findings revealed organizing pneumonia in seven patients and pulmonary hemorrhage in two patients. On HRCT at onset, patients with DAD had more geographic appearance than those without DAD (89% vs. 44%). In patients with geographic appearance and elevated KL-6 (> 500 U/mL), the sensitivity and specificity for DAD diagnosis were 56% and 100%, respectively. All three patients with no geographic appearance and normal KL-6 did not have DAD.

Conclusions: Geographic appearance on HRCT combined with KL-6 levels may predict the presence of DAD in patients with ARDS.
Background

Acute respiratory distress syndrome (ARDS) is characterized by an acute onset of hypoxemia with bilateral pulmonary infiltrates on chest radiography, secondary to underlying disorders associated with lung injury caused by nonspecific hyperinflammation with neutrophils. Diffuse alveolar damage (DAD) is the histopathological hallmark of ARDS [1, 2]. The presence of DAD is challenging to detect without lung biopsy, but this procedure is invasive, and samples are usually not obtained in patients with ARDS.

The Berlin definition has traditionally been used as a criterion to clinically define ARDS. A study analyzing 712 autopsied patients showed that the sensitivity and specificity of the Berlin definition to diagnose DAD were 89% and 63%, respectively [2]. Although the Berlin definition is advantageous for screening due to its high sensitivity, its low specificity means that some of the identified cases follow a clinical course that differs from that of DAD. ARDS patients without DAD present heterogeneous histopathologic findings, including organizing pneumonia and infection [3]. This is one of the reasons why it is difficult to elucidate the molecular mechanisms of ARDS and to develop specific therapies. Noninvasive methods to identify DAD are therefore an unmet need [4].

Previous studies reported that a lower ratio of arterial oxygen partial pressure to fractional inspired oxygen (PaO2/FiO2), extensive opacities involving the four quadrants, and increased dynamic driving pressure were associated with DAD [2, 5, 6]. However, one study with 258 ARDS patients who underwent open lung biopsy concluded that DAD could not be predicted clinically [7]. Other findings, such as elevated levels of Krebs von den Lungen-6 (KL-6) and geographic appearance on high-resolution computed tomography (HRCT), have also been associated with DAD. Several previous studies have reported that elevated KL-6 levels are associated with ARDS diagnosis in at-risk populations and ARDS-related mortality [8, 9]. Moreover, geographic appearance is currently considered a typical HRCT finding in ARDS cases [10], and a previous study that evaluated autopsy results from ARDS cases revealed these findings to be consistent with the exudative phase of DAD [11]. However, few reports have examined the association between these findings and DAD in detail.

This study aimed to investigate the relationship between DAD and clinical findings, including KL-6 and geographic appearance, in ARDS patients and to identify more specific diagnostic criteria for DAD.

Methods

Subjects

Consent for autopsy is routinely requested from relatives of patients who die in our institution. Among all autopsy cases at our hospital in Japan between January 2006 and March 2021, patients with ARDS who met the Berlin definition criteria were included. Eligible patients were adults (≥16 years old) and patients who required ventilation, including noninvasive ventilation, for respiratory failure; those with “do not intubate order” were also included. Patients with chronic interstitial lung disease were excluded.

Data collection

Medical records were reviewed retrospectively to analyze demographic information, underlying illness, primary risk factor of ARDS, laboratory and radiological data, as well as medical treatment and clinical outcomes. For laboratory data, including KL-6, values at diagnosis were reviewed. In our facility, KL-6 is tested in most patients with ARDS to investigate the cause, but not all patients are tested. Missing values are noted in the results section and in the tables.

HRCT assessment

In our facility, all patients suspected of ARDS underwent whole-lung volumetric HRCT scanning of the chest at diagnosis using a multidetector-row CT scan to rule out chronic interstitial lung disease, infection, pleural effusion, or lung collapse.

HRCT scans at onset were evaluated by a respiratory specialist and a radiology specialist, blinded to the patients’ clinical characteristics and study outcomes. Disagreements between observers were resolved by consensus. We evaluated the presence of the following specific HRCT findings: ground-glass opacity, consolidation, fibrosis, traction bronchiectasis, honeycombing, and geographic appearance. Geographic appearance was defined as a well-circumscribed infiltration partially spared in secondary pulmonary lobule units and a similar appearance of clear demarcation formed by the coastline against the sea (Fig. 1) [11, 12]. The presence of these findings was assessed qualitatively (either yes or no).
Pathological assessment
A postmortem study was performed within 24 h of death. After removal from the thorax, the lungs were inflated with 10% formalin and fixed in a block of 10% formalin. After 48 h, the seedlings were cut into slices of 3 cm thickness. The samples for microscopic analysis were obtained from each pulmonary lobe. Patients were classified as having DAD if they had hyaline membranes, even if the membranes were present in only one lobe, as this finding could represent an incipient form of DAD [2].

Statistical analyses
Data are presented as median (range) for continuous variables and as frequencies (percentage) for categorical variables. Categorical variables were compared using Fisher’s exact test, and continuous variables were compared using the Mann–Whitney U test. All statistical tests were two-tailed, and significance was set at $P \leq 0.05$. Sensitivity, specificity, and likelihood ratio for identifying ARDS patients with DAD were calculated for all factors associated to a significant $P$ value. All analyses were performed using R software, version 3.5.2 (R Foundation for Statistical Computing, Vienna, Austria).

Results
Of the 767 patients who underwent autopsy during the study period, 27 patients met the Berlin definition criteria and were diagnosed with ARDS prior to death (median age: 79 years, 19 men), of whom 18 (66%) had DAD and 9 (33%) had no DAD. Among the non-DAD group, histopathologic findings revealed organizing pneumonia in seven patients and pulmonary hemorrhage in two patients.

Table 1 presents the clinical characteristics of the patients with and without DAD. The primary causes of ARDS included pneumonia in 10 (56%) and connective tissue disease in 3 patients (17%) with DAD, and pneumonia in 5 (56%) and drug-induced pneumonitis in 2 patients (22%) without DAD. The severity of ARDS at diagnosis was mild in 2 (7%) patients, moderate in 19 (70%) patients, and severe in 6 (22%) patients. One patient of the 27 did not have KL-6 measured at diagnosis. Laboratory data at diagnosis showed that patients with DAD had higher KL-6 levels than those without DAD. The upper limit of normal for KL-6 (500 U/ml) was higher in 11 patients (65%) in the DAD group compared with the 1 (11%) in the non-DAD group. Approximately half of all patients received corticosteroids to treat their ARDS, in most cases in the form of methylprednisolone pulse therapy.

Table 2 shows a comparison of HRCT findings between the patients with and without DAD. The patients with DAD had more geographic appearance than those without DAD (16 [89%] vs. 4 [44%], $P=0.023$). The sensitivity and specificity of the presence of geographic appearance for the diagnosis of DAD were 89% (95% confidence interval [CI] 65–99%) and 56% (95% CI 21–86%), respectively. The sensitivity and specificity for the diagnosis of DAD were examined by combining the KL-6 values that differed the most in proportion between the patients with and without DAD among the laboratory findings. The specificity of geographic appearance and $\geq 500$ U/mL KL-6 improved to 100% (95% CI 56–100%) (Table 3).

Discussion
In this study, we demonstrated that the presence of geographic appearance on HRCT and elevated serum KL-6 levels are predictors of DAD in patients with ARDS. ARDS is clinically diagnosed based on the Berlin definition; however, considering these laboratory and radiological findings, it is possible to diagnose ARDS alongside DAD.

Primack et al. first reported that geographic appearance represents HRCT findings in ARDS [12]. According to a later study by Ichimon et al. using autopsy cases of ARDS, postmortem HRCT of the lungs showed geographic...
### Table 1: Demographic and clinical characteristics between patients with DAD and non-DAD

| Characteristic                      | Total (n = 27) | DAD (n = 18) | Non-DAD (n = 9) | P value |
|-------------------------------------|----------------|--------------|-----------------|---------|
| Age, years                          | 79 (62–92)     | 79 (62–92)   | 80 (66–91)      | 0.757   |
| Male                                | 19 (70)        | 13 (72)      | 6 (67)          | 1.000   |
| BMI                                 | 22.1 (16.4–28.8)| 21.9 (17.1–28.8)| 22.6 (16.4–26.2)| 0.471   |
| PaO$_2$/FiO$_2$                      | 142 (48–258)  | 142 (48–203) | 142 (60–258)    | 0.877   |
| APACHE II score                     | 29 (18–44)     | 28 (21–41)   | 34 (18–44)      | 0.469   |
| **Severity at diagnosis**           |                |              |                 | 0.655   |
| Mild                                | 2 (7)          | 1 (5)        | 1 (11)          |         |
| Moderate                            | 19 (70)        | 12 (67)      | 17 (78)         |         |
| Severe                              | 6 (22)         | 5 (28)       | 1 (11)          |         |
| **Ventilation**                     |                |              |                 | 0.683   |
| Noninvasive ventilation             | 10 (3.7)       | 6 (33)       | 4 (44)          |         |
| Mechanical ventilation              | 17 (63)        | 12 (67)      | 5 (56)          |         |
| **Underlying diseases**             |                |              |                 |         |
| Diabetes mellitus                   | 6 (22)         | 3 (17)       | 3 (33)          | 0.367   |
| Malignance                          | 6 (22)         | 3 (17)       | 3 (33)          | 0.367   |
| Immunosuppression                   | 5 (19)         | 2 (11)       | 3 (33)          | 0.295   |
| End stage renal disease             | 1 (4)          | 0 (0)        | 1 (11)          | 0.333   |
| **Primary risk factor of ARDS**     |                |              |                 | 0.916   |
| Pneumonia                           | 15 (56)        | 10 (56)      | 5 (56)          |         |
| Connective tissue disease           | 4 (15)         | 3 (17)       | 1 (11)          |         |
| Drug-induced                        | 3 (11)         | 1 (6)        | 2 (22)          |         |
| Sepsis                              | 2 (7)          | 1 (6)        | 1 (11)          |         |
| Malignancy                          | 1 (4)          | 1 (6)        | 0 (0)           |         |
| Aspiration                          | 1 (4)          | 1 (6)        | 0 (0)           |         |
| Radiation                           | 1 (4)          | 1 (6)        | 0 (0)           |         |
| **Duration of ARDS before death, d**| 18 (1–51)      | 18 (4–51)    | 18 (1–40)       | 0.410   |
| **Laboratory data at diagnosis**    |                |              |                 |         |
| WBC, per mm$^3$                     | 10,300 (300–37,800) | 11,200 (300–37,800) | 10,300 (2,300–30,000) | 0.877   |
| CRP, mg/dL                          | 13.6 (3.5–39.5) | 15.3 (3.5–39.5) | 11.2 (5.5–21.2)  | 0.291   |
| Albumin, g/dL                       | 2.5 (1.4–3.3)  | 2.5 (1.4–3.2) | 2.4 (1.4–3.3)   | 0.570   |
| Creatinine, mg/dL                   | 1.14 (0.27–4.64)| 1.13 (0.50–4.56)| 1.33 (0.27–4.64)| 0.471   |
| LDH, U/L                            | 343 (212–1,192)| 425 (212–1,192)| 317 (233–705)   | 0.345   |
| KL-6*, U/mL                         | 413 (194–1,780)| 760 (194–1,780)| 322 (229–1,322) | 0.090   |
| KL-6* > 500 U/mL                    | 12 (44)        | 11 (65)      | 1 (11)          | 0.014   |
| **Treatment**                       |                |              |                 |         |
| Corticosteroid administration       | 14 (52)        | 10 (56)      | 4 (44)          | 0.695   |
| Methylprednisolone pulse therapy$^\dagger$ | 13 (48) | 10 (56) | 3 (33) | 0.420   |
| **Autopsy findings**                |                |              |                 |         |
| Weight of two lungs, g              | 1,380 (545–4,605)| 1,455 (675–4,605)| 1,100 (545–2,375)| 0.143   |
| DAD                                 | 18 (67)        | 18 (100)     | –               |         |
| Organizing pneumonia                | 7 (26)         | –            | 7 (78)          |         |
| Pulmonary hemorrhage                | 2 (7)          | –            | 2 (22)          |         |

Continuous variables are expressed as medians (ranges), and categorical data are expressed as n (%).

APACHE: Acute Physiology and Chronic Health Evaluation, BMI: body mass index, CRP: C-reactive protein, DAD: diffuse alveolar damage, KL-6: Krebs von den Lungen-6, LDH: lactate dehydrogenase, PaO$_2$/FiO$_2$: arterial oxygen partial pressure/fractional inspired oxygen, WBC: white blood cell

$^\dagger$ Total n = 26; one case of non-DAD had a missing value

$^\dagger$ $\geq$ 500 mg/day for 3 days
appearance with focally spared regions, variably involving several lobules and segments, which revealed findings consistent with the exudative phase of DAD on histopathologic examination [11]. This geographic appearance is currently considered a typical HRCT finding in ARDS [10]. However, geographic appearance is a finding that is evident in various conditions, including pulmonary edema, pulmonary hemorrhage, pneumocystis pneumonia, and acute eosinophilic pneumonia [13]. In fact, our study showed that it has a specificity of only 56%, and therefore the presence of geographic appearance by itself is not sufficient for a DAD diagnosis. However, to the best of our knowledge, this study based on autopsy cases is the first to show an association between geographic appearance and DAD in patients with ARDS.

Our study also suggests that DAD patients had higher KL-6 levels than those without DAD. KL-6 is classified as a human MUC1 mucin protein and is one of the key molecules in interstitial lung diseases [14]. Several previous studies have reported that elevated KL-6 levels are associated with ARDS diagnosis in at-risk populations and ARDS mortality [8, 9]. However, no previous studies have reported an association between DAD and KL-6 levels. As for the mechanism of blood uptake of KL-6, the primary cellular source of KL-6 is regenerating type II pneumocytes in the affected lung; moreover, both the destruction of the alveolar-capillary barrier and the enhancement of alveolar-capillary permeability are necessary for the leakage of KL-6 into the systemic circulation [14]. It seems logical that KL-6 would be higher in patients with DAD than in those with OP or pulmonary hemorrhage, given that endothelial and epithelial damage occur, increasing vascular permeability in the exudative phase of DAD [15]. Renal dysfunction is another known source of KL-6, although there is no known association between serum and urine KL-6 levels [16]. In this study, no significant difference in creatinine levels was observed between the DAD and non-DAD groups, suggesting that the increase in KL-6 levels was due to lung injury. KL-6 was by itself a good predictor of DAD presence, but the combination of geographic appearance and KL-6 may further increase the specificity of the diagnosis.

ARDS is a heterogeneous syndrome. Although DAD is the histopathological hallmark of ARDS, the Berlin definition of ARDS lacks specificity using DAD as the reference standard; a study analyzing 712 autopsied patients showed that the sensitivity and specificity were 89% and 63%, respectively [2]. The Berlin definition has high sensitivity and is an excellent screening tool for diagnosing DAD in an emergency setting. However, high specificity is required for the subsequent accurate diagnosis of DAD. Our method has a high specificity, thus allowing for a more accurate detection of DAD in ARDS patients. The presence or absence of DAD impacts the response to treatment and prognosis, which should be considered in ARDS management. Importantly, the association

| HRCT findings          | Total (n = 27) | DAD (n = 18) | Non-DAD (n = 9) | P value |
|------------------------|---------------|-------------|----------------|---------|
| Ground-glass opacity   | 27 (100)      | 18 (100)    | 9 (100)        | NA      |
| Consolidation          | 19 (70)       | 14 (78)     | 5 (56)         | 0.375   |
| Fibrosis               | 5 (19)        | 3 (17)      | 2 (22)         | 1.000   |
| Honeycombing           | 1 (4)         | 1 (6)       | 0 (0)          | 1.000   |
| Traction bronchiectasis| 20 (74)       | 14 (78)     | 6 (67)         | 0.653   |
| Volume loss            | 23 (85)       | 16 (89)     | 7 (78)         | 0.582   |
| Geographic appearance  | 21 (78)       | 16 (89)     | 4 (44)         | 0.023   |

| Table 2 HRCT findings at onset between the patients with DAD and non-DAD |

Data are expressed as n (%)

HRCT high-resolution computed tomography, DAD diffuse alveolar damage

| Table 3 Sensitivity and specificity of KL-6 and geographic appearance for the diagnosis of DAD |

| Sensitivity, % (95% CI) | Specificity, % (95% CI) | Positive likelihood ratio (95% CI) | Negative likelihood ratio (95% CI) |
|------------------------|-------------------------|-----------------------------------|-----------------------------------|
| KL-6 > 500 U/mL        | 61 (36–83)              | 89 (52–100)                       | 5.5 (0.8–36.2)                    | 0.4 (0.2–0.8) |
| Geographic appearance  | 89 (65–99)              | 56 (21–86)                        | 2.0 (0.9–4.2)                    | 0.2 (0.05–0.8) |
| KL-6 > 500 U/mL and    | 56 (31–79)              | 100 (56–100)                      | NA                                | 0.4 (0.3–0.7) |

CI confidence interval, KL-6 Krebs von den Lungen-6
between the combination of geographic appearance on HRCT and KL-6 levels and DAD should be validated in another larger study to establish a detection method for DAD, which may ensure a better understanding of the pathogenesis and treatment of ARDS.

One of the limitations of our study is that the CT scan and pathological evaluation were not simultaneously carried out. In other words, as the HRCT findings of ARDS change over the clinical course of the disease, the HRCT findings evaluated in this study may not directly reflect the pathological findings at autopsy. However, it is likely that lung pathology was consistent from the time of CT scan to the time of death, and it is clinically important to predict DAD from imaging results at diagnosis. Second, since this study was a single-center retrospective study including only autopsy cases, the sample size was small. Moreover, only patients with ARDS for whom autopsies were performed were included in this study, and the possibility of unintentional selection bias could not be ruled out. Therefore, further validation in clinical trials is required to generalize our results.

Conclusions

Many patients with DAD on autopsy examination have geographic appearance on HRCT at onset and higher KL-6 levels. The presence of geographic appearance on HRCT combined with KL-6 ≥ 500 is a good predictor of the development of DAD in patients with ARDS.

Abbreviations

APACHE: Acute physiology and chronic health evaluation; ARDS: Acute respiratory distress syndrome; CI: Confidence interval; CRP: C-reactive protein; DAD: Diffuse alveolar damage; FiO2: Fractional inspired oxygen; HRCT: High-resolution computed tomography; KL-6: Krebs von den Lungen-6; LDH: Lactate dehydrogenase; PaO2: Arterial oxygen partial pressure.

Acknowledgements

We would like to thank Editage (http://www.editage.jp) for English language editing.

Prior abstract publication/presentation

Preliminary results of this work were reported at the Annual American Thoracic Society, San Francisco (USA), May 2022.

Author contributions

RI and DY had full access to all the data in the study and take responsibility for the data's integrity and the accuracy of the data analysis. RI, YT, and NN contributed substantially to the study design, data analysis and interpretation, and manuscript writing. TN, CS, SR, KO, AK, and TJ critically reviewed and approved the final version of the manuscript. All authors read and approved the final manuscript.

Funding

This study received no funding.

Availability of data and materials

The datasets generated and/or analyzed during the current study are not publicly available due to confidentiality and to safeguard accurate data interpretation, but are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

This retrospective study was approved by the institutional review board of St. Luke's International Hospital (Institutional Review Board No. 19-R121). The requirement for informed consent was waived by the institutional Review board of St. Luke's International Hospital owing to the retrospective study design. This study was conducted in accordance with the Declaration of Helsinki.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1 Department of Pulmonary Medicine, Thoracic Center, St. Luke's International Hospital, 9-1, Akashi-cho, Chuo City, Tokyo 104-8560, Japan. 2 Department of Radiology, St. Luke's International Hospital, Tokyo, Japan.

Received: 29 June 2022 Accepted: 5 August 2022

Published online: 11 August 2022

References

1. Bellani G, Laffey JG, Pham T, Fan E, Brochard L, Esteban A, et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA. 2016;315(8):788–800.
2. Thille AW, Esteban A, Fernández-Segoviano P, Rodríguez JM, Aramburu JA, Peñuelas O, et al. Comparison of the berlin definition for acute respiratory distress syndrome with autopsy. Am J Respir Crit Care Med. 2013;187(7):761–7.
3. Park J, Lee YJ, Lee J, Park SS, Cho YJ, Lee SM, et al. Histopathologic heterogeneity of acute respiratory distress syndrome revealed by surgical lung biopsy and its clinical implications. Korean J Intern Med. 2018;33(3):532–40.
4. Cardinal-Fernandez P, Lorente JA, Ballen-Barragan A, Matute-Bello G. Acute respiratory distress syndrome and diffuse alveolar damage: new insights on a complex relationship. Ann Am Thorac Soc. 2017;14(8):844–50.
5. Lorente JA, Cardinal-Fernandez P, Muñoz D, Frutos-Vivar F, Thille AW, Jaramillo C, et al. Acute respiratory distress syndrome in patients with and without diffuse alveolar damage: an autopsy study. Intensive Care Med. 2015;41(11):1921–30.
6. Thille AW, Peñuelas O, Lorente JA, Fernández-Segoviano P, Rodríguez JM, Aramburu JA, et al. Predictors of diffuse alveolar damage in patients with acute respiratory distress syndrome: a retrospective analysis of clinical autopsies. Crit Care. 2017;21(1):254.
7. Cardinal-Fernandez P, Ortiz G, Chang C-H, Kao K-C, Bertreau E, Philipponnet C, et al. Predicting the impact of diffuse alveolar damage through open lung biopsy in acute respiratory distress syndrome—the PREDATOR study. J Clin Med. 2019;8(6):829.
8. Sato H, Callister ME, Mumbry S, Quinlan GJ, Welsh KI, duBois RM, et al. KL-6 levels are elevated in plasma from patients with acute respiratory distress syndrome. Eur Respir J. 2004;23(1):142–5.
9. Terpstra ML, Aman J, van Nieuw Amerongen GP, Groeneveld ABJ. Plasma biomarkers for acute respiratory distress syndrome: a systematic review and meta-analysis. Crit Care Med. 2014;42(3):691–700.
10. Galvin JR, Frazier AA, Franks TJ. Collaborative radiologic and histopathologic assessment of fibrotic lung disease. Radiology. 2010;255(3):692–706.
11. Ichikado K, Jokohk T, Ikezoe J, Takeuchi N, Kohno N, Arisawa J, et al. Acute interstitial pneumonia: high-resolution CT findings correlated with pathology. Am J Roentgenol. 1997;168(2):333–8.
12. Primmack SL, Hartman TE, Ikezoe J, Akira M, Sakataki M, Muller NL. Acute interstitial pneumonia: radiographic and CT findings in nine patients. Radiology. 1993;188(3):817–20.
13. Kligerman SJ, Henry T, Lin CT, Franks TJ, Galvin JR. Mosaic attenuation: etiology, methods of differentiation, and pitfalls. Radiographics. 2015;35(5):1360–80.
14. Ishikawa N, Hatton N, Yokoyama A, Kohno N. Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases. Respir Investig. 2012;50(1):3–13.
15. Spadaro S, Park M, Turrini C, Tunstall T, Thwaites R, Mauri T, et al. Biomarkers for acute respiratory distress syndrome and prospects for personalised medicine. J Inflamm. 2019;16:1.
16. Zhang ZY, Ravassa S, Pejchinovski M, Yang WY, Zürbig P, López B, et al. A urinary fragment of mucin-1 subunit α is a novel biomarker associated with renal dysfunction in the general population. Kidney Int Rep. 2017;2(5):811–20.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.